disease

In: Finance

Artur Plawgo uniQure (NASDAQ:QURE) shares traded higher premarket Tuesday after the Dutch biotech posted the latest data from its Phase 1/2 clinical trials for AMT-130, an investigational gene therapy for Huntington’s disease, a rare, inherited neurodegenerative disorder. Based on a Mar. 31 data cut of 21 patients, the company saidContinue Reading

In: Finance

Sundry Photography Merck (NYSE:MRK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its lung disease therapy Winrevair in combination with other medications for certain adults with pulmonary arterial hypertension (PAH). EMA’s Committee for Medicinal Products for Human Use (CHMP) issued aContinue Reading